C4 Therapeutics, Inc. has grown revenue 30% a year over three years and −5.9% a year over five. Revenue growth, 3-year annual rate: +30% (Biotechnology median +17%). Revenue growth, 5-year rate: −5.9%, growth has picked up over the last three years. Years of annual history on file: 7, FY2019 to FY2025, as filed.

CCCCC4 Therapeutics, Inc.

Healthcare

$2.85+26% 1Y

$2.85

$1.7152 weeks$4.67

Is it growing?

Mixed

Neither accelerating nor breaking down: nothing decisive, though operating margin widening (+97.5 points).

1 good, 1 neutral, 1 without data

Revenue trend+2% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Margin direction+97.5 points operating

Trailing-twelve-month operating margin, -341.5% now against -439.0% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is CCCC growing?

C4 Therapeutics, Inc. has grown revenue 30% a year over three years and −5.9% a year over five.

+30%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: −5.9%
Revenue growth, 5-year rate · +30% over three · growth has picked up over the last three years
Years of annual history on file: 7
Years of annual history on file · FY2019 to FY2025, as filed

Details›